C3 glomerulonephritis
see-three gluh-mer-yoo-loh-nef-ritis
Also known as: C3GN, Complement 3 glomerulonephritis
At a Glance
What is C3 glomerulonephritis?
C3 glomerulonephritis is a rare kidney disorder that affects the glomeruli, which are tiny filtering units in the kidneys. It is caused by abnormal activation of the complement system, part of the immune system, leading to inflammation and damage in the kidneys. Over time, this condition can progress to chronic kidney disease or even kidney failure if not managed properly. Early symptoms may include blood in the urine, swelling, and high blood pressure, while later stages might present with more severe kidney dysfunction. Early diagnosis is crucial to manage the condition effectively and prevent long-term damage. The condition can significantly impact family life due to the need for ongoing medical care and potential lifestyle adjustments. Prognosis varies, with some individuals maintaining stable kidney function for years, while others may progress to kidney failure. Daily life for affected individuals may involve regular medical check-ups, dietary restrictions, and possibly medication to control symptoms. Support from healthcare providers and family is essential to manage the emotional and physical challenges of the disease. Patients may need to avoid certain medications that can worsen kidney function. Genetic counseling might be recommended for families with a history of the condition. Understanding and managing the disease can help maintain quality of life for those affected.
Medical Definition
C3 glomerulonephritis is characterized by predominant C3 deposition in the glomeruli without significant immunoglobulin deposits, indicating dysregulation of the alternative complement pathway. Histologically, it presents with mesangial proliferation and capillary wall thickening, often resembling membranoproliferative glomerulonephritis. It is classified under C3 glomerulopathy, which includes dense deposit disease as a related condition. Epidemiologically, it is considered an ultra-rare disease with a prevalence of approximately 1 in 1,000,000 individuals. The disease course is variable, with some patients experiencing slow progression to end-stage renal disease, while others maintain stable kidney function. Management often involves complement pathway inhibitors and supportive renal care to slow disease progression.
C3 glomerulonephritis Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Hematuria manifests as blood in the urine, which can be visible to the naked eye or detected microscopically. It is caused by damage to the glomeruli, allowing red blood cells to leak into the urine. Over time, hematuria may become more pronounced as kidney function deteriorates. This symptom can cause anxiety and distress in patients, and regular monitoring and treatment can help manage its progression.
Proteinuria is characterized by an excess of protein in the urine, often detected during routine urine tests. It occurs due to increased permeability of the glomerular basement membrane, allowing proteins to pass through. As the disease progresses, proteinuria can lead to nephrotic syndrome, characterized by swelling and increased risk of infections. Managing proteinuria involves medications like ACE inhibitors and lifestyle changes to reduce kidney strain.
Edema presents as swelling in various parts of the body, particularly in the legs, ankles, and around the eyes. It results from the kidney's inability to maintain fluid balance, leading to fluid retention. Over time, edema can worsen, causing discomfort and mobility issues. Diuretics and dietary modifications can help manage fluid retention and alleviate symptoms.
Common
Hypertension, or high blood pressure, often accompanies kidney diseases like C3 glomerulonephritis. It is caused by the kidney's impaired ability to regulate blood pressure and fluid balance. If left untreated, hypertension can exacerbate kidney damage and increase cardiovascular risks. Blood pressure control through medication and lifestyle changes is crucial for managing this symptom.
Fatigue is a common symptom that manifests as persistent tiredness and lack of energy. It is often due to anemia or the body's increased effort to compensate for impaired kidney function. As kidney function declines, fatigue can become more severe, impacting daily activities and quality of life. Addressing underlying causes, such as anemia, and ensuring adequate rest can help manage fatigue.
Decreased urine output is a sign of declining kidney function, where the kidneys produce less urine than normal. This occurs as the glomeruli become less efficient at filtering blood. Over time, oliguria can lead to fluid overload and electrolyte imbalances. Monitoring fluid intake and output, along with medical interventions, can help manage this condition.
Less Common
Foamy urine is often an early sign of proteinuria, where excess protein in the urine causes bubbles or foam. It occurs due to the presence of proteins like albumin that alter the surface tension of urine. While initially mild, foamy urine can become more noticeable as proteinuria worsens. Patients are advised to report this symptom to their healthcare provider for further evaluation and management.
Nausea can occur as a result of toxin buildup in the body due to impaired kidney function. It is often a consequence of uremia, where waste products accumulate in the blood. As kidney function continues to decline, nausea can become more frequent and severe, affecting appetite and nutritional status. Dietary adjustments and medications can help alleviate nausea and improve patient comfort.
What Causes C3 glomerulonephritis?
C3 glomerulonephritis is primarily associated with mutations in the CFH, CFI, C3, and CFHR5 genes, located on chromosome 1. These genes encode proteins that are crucial components of the complement system, which plays a role in innate immunity. Mutations in these genes can lead to structural changes in the proteins, impairing their ability to regulate complement activation. This dysregulation results in uncontrolled activation of the complement cascade, particularly the alternative pathway. Consequently, there is excessive deposition of complement components, such as C3, in the glomeruli of the kidneys. This deposition triggers local inflammation and immune cell recruitment, leading to glomerular damage. The inflammatory response can cause further tissue injury and fibrosis, disrupting normal kidney function. As the disease progresses, proteinuria and hematuria develop due to the damaged glomerular filtration barrier. The variability in symptoms and severity among patients can be attributed to the specific genetic mutations and environmental factors influencing disease progression. Some patients may experience rapid kidney function decline, while others have a more indolent course. The immune response, particularly involving complement proteins, plays a significant role in disease pathogenesis and progression. Neuroinflammation is not typically a feature of C3 glomerulonephritis, as the disease primarily affects renal tissues. However, systemic inflammation can have indirect effects on other organs. The pattern of symptoms, such as edema and hypertension, arises from the kidney's impaired ability to filter blood and maintain fluid balance. Genetic heterogeneity and the presence of additional modifying factors contribute to the observed variability in clinical presentation and outcomes.
How is C3 glomerulonephritis Diagnosed?
Typical age of diagnosis: C3 glomerulonephritis is typically diagnosed in young adults, often in their 20s or 30s, following the presentation of symptoms such as hematuria and proteinuria. Diagnosis is frequently prompted by routine urinalysis or investigation of renal symptoms.
Clinicians look for signs of kidney dysfunction, such as hematuria, proteinuria, and hypertension. A detailed medical history is taken to identify any familial patterns or previous infections. Physical examination may reveal edema or hypertension, which suggests renal involvement. This step helps determine the need for further diagnostic testing and rule out other causes of renal symptoms.
Ultrasound is the primary imaging modality used, revealing kidney size and possible structural abnormalities. Findings such as increased echogenicity can suggest chronic kidney disease. Imaging helps confirm the presence of renal pathology and excludes obstructive uropathy. It aids in differentiating C3 glomerulonephritis from other renal conditions with similar presentations.
Tests include serum complement levels, specifically C3, and urinalysis for proteinuria and hematuria. Low serum C3 levels and the presence of C3 deposits in the kidney are indicative. Abnormal results guide the clinician towards a diagnosis of C3 glomerulonephritis. These results help determine the need for a renal biopsy to confirm the diagnosis.
Genetic testing may involve sequencing genes such as CFH, CFI, and MCP. Mutations in these genes can lead to complement dysregulation, confirming the diagnosis. Results can provide a definitive diagnosis and guide treatment decisions. Genetic findings also inform family counseling regarding the hereditary nature of the condition.
C3 glomerulonephritis Treatment Options
Complement inhibitors, such as eculizumab, target the complement pathway to reduce kidney damage. Eculizumab specifically inhibits the C5 component, preventing the formation of the membrane attack complex. Clinical trials have shown efficacy in reducing proteinuria and stabilizing renal function. However, the high cost and risk of infections are significant limitations. Regular monitoring for side effects and effectiveness is necessary.
Renal rehabilitation includes exercises tailored to improve cardiovascular health and muscle strength. The goal is to enhance overall physical function and quality of life. Sessions are typically conducted 2-3 times per week, lasting about an hour each. Outcomes are measured by improvements in exercise capacity and daily functioning. Long-term benefits include reduced cardiovascular risk and improved mental health.
Indicated for patients with end-stage renal disease due to C3 glomerulonephritis. The procedure involves replacing the diseased kidney with a healthy donor kidney. Expected benefits include restored kidney function and improved quality of life. Surgical risks include rejection and infection, requiring lifelong immunosuppression. Post-operative care involves regular monitoring for signs of rejection and maintaining immunosuppressive therapy.
The care team includes nephrologists, dietitians, social workers, and mental health professionals. Interventions focus on managing symptoms, dietary modifications, and psychosocial support. Strategies include counseling and education to help patients and families cope with the disease. Family education is crucial for understanding the condition and its management. Long-term monitoring involves regular follow-ups to assess disease progression and treatment efficacy.
When to See a Doctor for C3 glomerulonephritis
- Severe swelling in legs and face — this could indicate acute kidney failure requiring immediate medical attention.
- Blood in urine — may signify significant kidney damage or severe inflammation necessitating urgent evaluation.
- Sudden onset of high blood pressure — could be a sign of rapidly progressing kidney disease, requiring emergency intervention.
- Persistent fatigue — may indicate worsening kidney function; consult a nephrologist for further evaluation.
- Decreased urine output — could suggest declining kidney function; seek medical advice to assess kidney health.
- Unexplained weight gain — may be due to fluid retention associated with kidney issues; a healthcare provider should evaluate this symptom.
- Mild swelling in ankles — monitor at home and report to a doctor if it worsens or persists.
- Occasional foamy urine — can be normal but monitor for changes in frequency or severity and discuss with a doctor.
C3 glomerulonephritis — Frequently Asked Questions
Is this condition hereditary?
C3 glomerulonephritis can have a hereditary component, often following an autosomal dominant pattern. The probability of passing it to children is 50% if one parent carries the gene mutation. De novo mutations can occur, meaning the condition can appear without a family history. Carrier status can lead to varying degrees of disease expression. Genetic counseling is recommended for affected families to understand risks and implications.
What is the life expectancy for someone with this condition?
Life expectancy varies based on the age of onset and severity of the disease. Early diagnosis and treatment can improve outcomes, while factors like hypertension and proteinuria worsen prognosis. Mortality is often due to kidney failure or associated cardiovascular complications. Treatment, including immunosuppressive therapy, can extend survival and improve quality of life. Realistic expectations should include regular monitoring and lifestyle adjustments.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves a combination of clinical evaluation, laboratory tests, and kidney biopsy. The time from first symptoms to diagnosis can vary, often taking several months. Nephrologists are typically consulted for diagnosis and management. Delayed diagnosis may occur due to nonspecific symptoms and rarity of the condition. A kidney biopsy confirming C3 deposition is essential for definitive diagnosis.
Are there any new treatments or clinical trials available?
Current research focuses on complement pathway inhibitors and other targeted therapies. Gene therapy is being explored as a potential future treatment. Clinical trials can be found on ClinicalTrials.gov by searching for 'C3 glomerulonephritis'. Patients should ask their doctors about eligibility for trials and potential benefits. New treatments may take several years to become widely available.
How does this condition affect daily life and activities?
C3 glomerulonephritis can impact mobility and self-care due to fatigue and swelling. Educational and occupational activities may be affected by frequent medical appointments and health fluctuations. Social and emotional challenges include coping with a chronic illness and potential isolation. Family burden may involve caregiving responsibilities and financial strain. Supportive measures include dietary modifications, physical therapy, and mental health support.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis.
Ponticelli C, Calatroni M, Moroni G · Front Med (Lausanne) · 2023 · PMID: 38076230
- 2.C3 glomerulopathy - understanding a rare complement-driven renal disease.
Smith RJH, Appel GB, Blom AM et al. · Nat Rev Nephrol · 2019 · PMID: 30692664
- 3.[Membranoproliferative glomerulonephritis and C3 glomerulopathy].
Hohenstein B, Amann K, Menne J · Internist (Berl) · 2019 · PMID: 30859280
- 4.C3 Glomerulonephritis Associated with Monoclonal Gammopathy of Renal Significance.
Gomes-Alves I, Castro-Ferreira I · Acta Med Port · 2021 · PMID: 33819437
- 5.C3 Glomerulopathy: Pathogenesis and Treatment.
Ahmad SB, Bomback AS · Adv Chronic Kidney Dis · 2020 · PMID: 32553242
- 6.C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS, Santoriello D, Avasare RS et al. · Kidney Int · 2018 · PMID: 29310824
- 7.C3 glomerulonephritis and CFHR5 nephropathy.
Gale DP, Maxwell PH · Nephrol Dial Transplant · 2013 · PMID: 23125424
- 8.C3 glomerulopathy: Understanding an ultra-rare complement-mediated renal disease.
Heiderscheit AK, Hauer JJ, Smith RJH · Am J Med Genet C Semin Med Genet · 2022 · PMID: 35734939
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-17